Latest Biotech News

Illumina appointed former NHGRI director Eric Green as chief medical officer, a strategic hire as the sequencing leader pivots toward clinical applications and healthcare integration. Green will...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to improve engagement between investors and emerging biotech companies and to accelerate capital formation for...

Aktis Oncology priced an upsized initial public offering that raised $318 million, marking the first biopharma IPO of 2026. The Boston-based radiopharmaceutical developer sold 17.65 million shares...

Eli Lilly agreed to acquire Ventyx Biosciences for approximately $1.2 billion in cash, adding oral NLRP3 inhibitors to Lilly’s inflammation pipeline. Lilly cited Ventyx’s mid‑stage clinical data...

Parabilis Medicines raised $305 million in a Series F financing to advance its corkscrew‑shaped peptide platform against intracellular and previously 'undruggable' protein targets. The round, led...

A team from MIT's CSAIL launched Boltz as a public benefit corporation and closed a $28 million seed round to commercialize open AI models for molecular structure prediction and therapeutic...

Researchers linked to the Baby KJ personalized CRISPR case and Jennifer Doudna launched Aurora Therapeutics with seed backing to develop grouped, mutation‑targeted gene‑editing therapies. Menlo...

Illumina appointed former NHGRI director Eric Green as chief medical officer, signaling a push to lean harder into clinical genomics and precision medicine. Green, who served 16 years at NHGRI,...

EpiBiologics closed a $107 million Series B to advance its EpiTAC protein‑degrader antibody platform and prepare its lead candidate EPI‑326 for first‑in‑human testing. The Bay Area company...

AirNexis Therapeutics raised $200 million in a Series A and acquired exclusive outside‑China rights to Haisco’s PDE3/4 inhibitor for COPD, funding development of AN01. The deal structure includes...

Alveus Therapeutics emerged with a $159.8 million Series A to advance an obesity program designed to mirror tirzepatide’s multimodal efficacy with potential dosing advantages. The company’s...

Krystal Biotech disclosed early clinical proof‑of‑concept data for a mutation‑agnostic gene therapy approach in cystic fibrosis and said it plans to pursue a pivotal development path. The company...

Aktis Oncology priced an upsized US IPO that raised $318 million, signaling renewed investor appetite for radiopharmaceutical platforms. The Boston-based developer sold 17.65 million shares at $18...

Eli Lilly agreed to acquire Ventyx Biosciences for $1.2 billion in cash, paying $14 per share, to add oral NLRP3 inhibitors to its inflammation pipeline. Lilly positioned the buyout as a strategic...

Parabilis Medicines closed a $305 million Series F to advance its Helicon peptide platform aimed at intracellular and previously 'undruggable' targets. The funding, led by major crossover and...

Protein‑degrader startup EpiBiologics raised $107 million in a Series B to advance EPI‑326, a bispecific degrader targeting oncogenic surface proteins, into first‑in‑human studies. The financing...

Aurora Therapeutics — cofounded and advised by gene‑editing pioneers including Jennifer Doudna and Fyodor Urnov — launched with seed backing to scale bespoke CRISPR therapies for ultra‑rare...

Illumina appointed Eric Green, former director of the National Human Genome Research Institute, as chief medical officer starting Feb. 2. The hire signals Illumina’s push to deepen clinical and...

Boltz, a public benefit corporation spun out of MIT CSAIL, launched with $28 million in seed funding to make high‑accuracy open AI models for molecular structure prediction and therapeutic design...

Pfizer entered a research collaboration with Gordian Bio to apply Gordian’s in vivo mosaic screening platform to prioritize obesity targets directly in visceral adipose tissue. The collaboration...